Ulcerative colitis: Rescue immune suppression for severe colitis—worth the risk?

Up to 30% of patients with refractory ulcerative colitis have steroid-resistant disease and, if cured with restorative proctocolectomy, could develop pouchitis. Ciclosporin and infliximab monotherapy have been used experimentally to tackle this problem. A recent study has assessed ciclosporin and infliximab as second-line therapies when one has failed.